Navigation Links
McMaster scientists find protein’s bad guy role in prostate cancer
Date:5/10/2011

Hamilton, ON (May 10, 2011) It's a disease affecting those closest to us our fathers, brothers and sons.

Prostate cancer impacts one in six men in Canada. Last year, roughly 24,600 men were diagnosed with the disease.

Most types of prostate cancer are curable if caught and treated early. But little is understood about the mechanisms that cause a tumour to metastasize and spread to other parts of the body.

Damu Tang, an associate professor of medicine in the Division of Nephrology of the McMaster University's Michael G. DeGroote School of Medicine and St. Joseph's Healthcare Hamilton, has spent nearly a decade and searched more than a million genes to better understand the molecular underpinnings of prostate cancer progression.

His research, published today in Nature Communications, shows for the first time the role of a specific protein MAN2C1 in prostate cancer development. The finding is significant because prostate cancer patients with increased levels of MAN2C1 appear to face more aggressive forms of the disease.

"This research could serve a diagnostic purpose in terms of likelihood of whether prostate cancers at early stages will progress into metastatic tumours," said Tang, who has a joint appointment in the Division of Urology, Department of Surgery at McMaster. "Patients with high levels of MAN2C1 may need more aggressive therapies when their cancers are still at early stages in order to prevent the development of metastatic cancer."

It's been known for some time that another protein, PTEN, is a powerful tumour suppressor. Clinical observations have shown that half of advanced prostate cancers either have no PTEN or reduced PTEN function.

Tang and his research team set out to understand how PTEN function becomes impaired in advanced prostate cancers. In the process, they discovered MAN2C1 and the role it plays in reducing PTEN function.

The research group found increases in the MAN2C1 protein in PTEN-positive prostate cancer cells dramatically increased the likelihood of cancers forming in mice. Additional research showed that in 659 prostate cancer patients, approximately 60 per cent of their prostate tumors had normal PTEN. Among these tumors, 80 per cent had increased MAN2C1.

The researchers concluded that increases in MAN2C1 in PTEN-positive prostate cancers enhance prostate cancer recurrence, meaning that patients with high levels of MAN2C1 have an increased risk of their tumors developing into metastatic cancer.

The next step for the researchers will be to look for ways to block the ability of MAN2C1 to impair PTEN function, Tang said. That could lead to the development of new therapies for patients with prostate cancer.


'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
905-525-9140 x22169
McMaster University
Source:Eurekalert

Related medicine news :

1. McMaster researcher leads development of promising drug for inflammation
2. McMaster study contradicts reports of problems with blood-thinner
3. Youth with IBD are less fit than their peers: McMaster study
4. McMaster vaccine has pet owners feline groovy
5. Scientists Pinpoint Area of Brain That Fears Losing Money
6. Scientists Discover How HIV Is Transmitted Between Men
7. Prevention Is Key Research Goal for Premature Babies, Scientists Say
8. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
9. Scientists find donut-shaped structure of enzyme involved in energy metabolism
10. Neuroscientists reveal new links that regulate brain electrical activity
11. Two UCSF Scientists to Receive Prestigious Dementia Research Honor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... Atlanta, Georgia (PRWEB) , ... May 26, 2016 ... ... a certificate in intellectual property (IP) to its specialty academic programs. , Answering ... joins the college’s existing certificate programs in health law, and environmental and land ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: